APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia Gene Therapy

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Selected research

Market Outlook & Growth Opportunities

Global Hemophilia Gene Therapy Market Outlook and Growth Opportunities 2026

Report ID 173894410421 December 2025192 pages

Choose your research edition.

Industry ResearchHemophilia Gene Therapy Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia Gene Therapy Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Hemophilia Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia Gene Therapy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia Gene Therapy Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.

This report provides an overview of the global Hemophilia Gene Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Hemophilia Gene Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemophilia Gene Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hemophilia Gene Therapy market.

Hemophilia Gene Therapy Segment by Company

Spark Therapeutics

Ultragenyx

Shire PLC

Sangamo Therapeutics

Bioverativ

BioMarin

uniQure

Freeline Therapeutics

Hemophilia Gene Therapy Segment by Type

Hemophilia A

Hemophilia B

Hemophilia Gene Therapy Segment by Application

Hemophilia A Gene Therapy

Hemophilia B Gene Therapy

Hemophilia Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hemophilia Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hemophilia Gene Therapy key companies, revenue, market share, and recent developments.

3. To split the Hemophilia Gene Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hemophilia Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hemophilia Gene Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Hemophilia Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemophilia Gene Therapy industry.

Chapter 3: Detailed analysis of Hemophilia Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hemophilia Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hemophilia Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hemophilia Gene Therapy Industry Trends Table 2. Hemophilia Gene Therapy Industry Drivers Table 3. Hemophilia Gene Therapy Industry Opportunities and Challenges Table 4. Hemophilia Gene Therapy Industry Restraints Table 5. Global Hemophilia Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hemophilia Gene Therapy Revenue Share by Company (2021-2026) Table 7. Global Hemophilia Gene Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hemophilia Gene Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Hemophilia Gene Therapy Company, Product Type & Application Table 10. Global Hemophilia Gene Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hemophilia Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Hemophilia A Table 15. Significant Companies of Hemophilia B Table 16. Global Hemophilia Gene Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Hemophilia Gene Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Hemophilia Gene Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Hemophilia Gene Therapy Sales Value Share by Type (2021-2026) Table 20. Global Hemophilia Gene Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hemophilia A Gene Therapy Table 22. Significant Companies of Hemophilia B Gene Therapy Table 23. Global Hemophilia Gene Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Hemophilia Gene Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Hemophilia Gene Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Hemophilia Gene Therapy Sales Value Share by Application (2021-2026) Table 27. Global Hemophilia Gene Therapy Sales Value Share by Application (2027-2032) Table 28. Global Hemophilia Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Hemophilia Gene Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Hemophilia Gene Therapy Sales Value Share by Region (2021-2026) Table 31. Global Hemophilia Gene Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Hemophilia Gene Therapy Sales Value Share by Region (2027-2032) Table 33. Global Hemophilia Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Hemophilia Gene Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Hemophilia Gene Therapy Sales Value Market Share by Country (2021-2026) Table 36. Global Hemophilia Gene Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Hemophilia Gene Therapy Sales Value Market Share by Country (2027-2032) Table 38. Spark Therapeutics Company Information Table 39. Spark Therapeutics Business Overview Table 40. Spark Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Spark Therapeutics Hemophilia Gene Therapy Product Portfolio Table 42. Spark Therapeutics Recent Development Table 43. Ultragenyx Company Information Table 44. Ultragenyx Business Overview Table 45. Ultragenyx Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Ultragenyx Hemophilia Gene Therapy Product Portfolio Table 47. Ultragenyx Recent Development Table 48. Shire PLC Company Information Table 49. Shire PLC Business Overview Table 50. Shire PLC Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Shire PLC Hemophilia Gene Therapy Product Portfolio Table 52. Shire PLC Recent Development Table 53. Sangamo Therapeutics Company Information Table 54. Sangamo Therapeutics Business Overview Table 55. Sangamo Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio Table 57. Sangamo Therapeutics Recent Development Table 58. Bioverativ Company Information Table 59. Bioverativ Business Overview Table 60. Bioverativ Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Bioverativ Hemophilia Gene Therapy Product Portfolio Table 62. Bioverativ Recent Development Table 63. BioMarin Company Information Table 64. BioMarin Business Overview Table 65. BioMarin Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. BioMarin Hemophilia Gene Therapy Product Portfolio Table 67. BioMarin Recent Development Table 68. uniQure Company Information Table 69. uniQure Business Overview Table 70. uniQure Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. uniQure Hemophilia Gene Therapy Product Portfolio Table 72. uniQure Recent Development Table 73. Freeline Therapeutics Company Information Table 74. Freeline Therapeutics Business Overview Table 75. Freeline Therapeutics Hemophilia Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio Table 77. Freeline Therapeutics Recent Development Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Hemophilia Gene Therapy Product Image Figure 2. Global Hemophilia Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Hemophilia Gene Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Hemophilia A Image Figure 8. Hemophilia B Image Figure 9. Global Hemophilia Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Hemophilia Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Hemophilia Gene Therapy Sales Value Share by Type (2021-2032) Figure 12. Hemophilia A Gene Therapy Image Figure 13. Hemophilia B Gene Therapy Image Figure 14. Global Hemophilia Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hemophilia Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hemophilia Gene Therapy Sales Value Share by Application (2021-2032) Figure 17. Global Hemophilia Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Hemophilia Gene Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Hemophilia Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Hemophilia Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Hemophilia Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Hemophilia Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Hemophilia Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Hemophilia Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Hemophilia Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Hemophilia Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Hemophilia Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Hemophilia Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Hemophilia A
  • Hemophilia B
Applications
  • Hemophilia A Gene Therapy
  • Hemophilia B Gene Therapy
Companies covered
  • Spark Therapeutics
  • Ultragenyx
  • Shire PLC
  • Sangamo Therapeutics
  • Bioverativ
  • BioMarin
  • uniQure
  • Freeline Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hemophilia Gene Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hemophilia Gene Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hemophilia Gene Therapy Market Dynamics
  1. 2.1 Hemophilia Gene Therapy Industry Trends
  2. 2.2 Hemophilia Gene Therapy Industry Drivers
  3. 2.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Hemophilia Gene Therapy Industry Restraints
3 Hemophilia Gene Therapy Market by Company
  1. 3.1 Global Hemophilia Gene Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Hemophilia Gene Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Hemophilia Gene Therapy Company Ranking (2024-2026)
  4. 3.4 Global Hemophilia Gene Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Hemophilia Gene Therapy Company Product Type and Application
  6. 3.6 Global Hemophilia Gene Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hemophilia Gene Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hemophilia Gene Therapy Market by Type
  1. 4.1 Hemophilia Gene Therapy Type Introduction
  2. 4.1.1 Hemophilia A
  3. 4.1.2 Hemophilia B
  4. 4.2 Global Hemophilia Gene Therapy Sales Value by Type
  5. 4.2.1 Global Hemophilia Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hemophilia Gene Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Hemophilia Gene Therapy Sales Value Share by Type (2021-2032)
5 Hemophilia Gene Therapy Market by Application
  1. 5.1 Hemophilia Gene Therapy Application Introduction
  2. 5.1.1 Hemophilia A Gene Therapy
  3. 5.1.2 Hemophilia B Gene Therapy
  4. 5.2 Global Hemophilia Gene Therapy Sales Value by Application
  5. 5.2.1 Global Hemophilia Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hemophilia Gene Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Hemophilia Gene Therapy Sales Value Share by Application (2021-2032)
6 Hemophilia Gene Therapy Regional Value Analysis
  1. 6.1 Global Hemophilia Gene Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hemophilia Gene Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hemophilia Gene Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hemophilia Gene Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hemophilia Gene Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Hemophilia Gene Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hemophilia Gene Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Hemophilia Gene Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hemophilia Gene Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hemophilia Gene Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hemophilia Gene Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Hemophilia Gene Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hemophilia Gene Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hemophilia Gene Therapy Sales Value Share by Country, 2025 VS 2032
7 Hemophilia Gene Therapy Country-level Value Analysis
  1. 7.1 Global Hemophilia Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hemophilia Gene Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hemophilia Gene Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hemophilia Gene Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hemophilia Gene Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hemophilia Gene Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hemophilia Gene Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Spark Therapeutics
  2. 8.1.1 Spark Therapeutics Company Information
  3. 8.1.2 Spark Therapeutics Business Overview
  4. 8.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
  6. 8.1.5 Spark Therapeutics Recent Developments
  7. 8.2 Ultragenyx
  8. 8.2.1 Ultragenyx Company Information
  9. 8.2.2 Ultragenyx Business Overview
  10. 8.2.3 Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
  12. 8.2.5 Ultragenyx Recent Developments
  13. 8.3 Shire PLC
  14. 8.3.1 Shire PLC Company Information
  15. 8.3.2 Shire PLC Business Overview
  16. 8.3.3 Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
  18. 8.3.5 Shire PLC Recent Developments
  19. 8.4 Sangamo Therapeutics
  20. 8.4.1 Sangamo Therapeutics Company Information
  21. 8.4.2 Sangamo Therapeutics Business Overview
  22. 8.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
  24. 8.4.5 Sangamo Therapeutics Recent Developments
  25. 8.5 Bioverativ
  26. 8.5.1 Bioverativ Company Information
  27. 8.5.2 Bioverativ Business Overview
  28. 8.5.3 Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
  30. 8.5.5 Bioverativ Recent Developments
  31. 8.6 BioMarin
  32. 8.6.1 BioMarin Company Information
  33. 8.6.2 BioMarin Business Overview
  34. 8.6.3 BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
  36. 8.6.5 BioMarin Recent Developments
  37. 8.7 uniQure
  38. 8.7.1 uniQure Company Information
  39. 8.7.2 uniQure Business Overview
  40. 8.7.3 uniQure Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
  42. 8.7.5 uniQure Recent Developments
  43. 8.8 Freeline Therapeutics
  44. 8.8.1 Freeline Therapeutics Company Information
  45. 8.8.2 Freeline Therapeutics Business Overview
  46. 8.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
  48. 8.8.5 Freeline Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst